PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 7653219

[Hematologic problems in systemic lupus erythematosus].

T Robak·E Robak·A Sysa-Jedrzejowska
View original source ↗Export metadata ↓

Abstract

Systemic lupus erythematosus (SLE) remains a disease of unknown origin, characterized by major alterations of both the cellular and the humoral arms of immunity. Hematological changes, including anaemia, leucopenia and thrombocytopenia, occur in more than one half of patients with this disease. Anaemia is the most common hematological abnormality seen in SLE. Its possible causes are anaemia of chronic disease (ACD), auto-immune haemolytic anaemia and hypoplastic anaemia. Leucopenia affects both granulocytic and lymphocytic lines and may be caused by autoantibodies. The influence of drugs, hypersplenism and marrow suppression are also possible. Thrombocytopenia occurs frequently and is almost invariably autoimmune. Patients with SLE are at increased risk of thrombosis. Haematological abnormalities in patients with this disease require careful long-term monitoring and prompt therapeutic intervention.

Explore related subjects

Autoimmune DiseasesHematologic DiseasesHumansLupus Erythematosus, SystemicEnglish AbstractJournal ArticleReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

T Robak, E Robak, A Sysa-Jedrzejowska. 1995. [Hematologic problems in systemic lupus erythematosus].. https://pubmed.ncbi.nlm.nih.gov/7653219/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2000

[Autoimmune dermatoses: new therapeutic strategies].

In the recent past, advances in both basic and clinical research have considerably contributed to the understanding of the cellular and molecular events that lead to autoimmune diseases. Nevertheless, current treatment protocols are essentially confined to systemic corticosteroids and cytotoxic agents. These are effective in controlling inflammation, however the occurrence of relapses after the treatment is stopped and the risks of toxicity and long-term immunosuppression necessitate the search for more selective strategies of immunointervention. Major efforts are directed towards therapies with increased cellular selectivity and, ideally, autoantigen specificity. Cyclosporine A, monoclonal antibodies (anti-CD4) and immunotoxins (IL-2 fusion toxins) currently constitute the main clinical orientation. At the experimental level, strategies are directed towards antigen-specific manipulation of costimulatory pathways (anti-gp39, CTLA4Ig), peptide therapy (MHC antagonism, TCR vaccination), and tolerance induction to the autoantigen (oral tolerization). Alternatively, intervention in the cytokine cascade of the inflammatory response by means of cytokine-induced immunomodulation (IL-4, IL-10) or cytokine antagonism (anti-TNF alpha) are strategies with a therapeutic potential. However, it must be borne in mind, that in animal models of antigen-induced autoimmune disease, it is simple to intervene in the development of autoimmunity, since the induction events are designed by the investigator. In contrast, in the majority of patients with autoimmune disease, we do not know whether a specific autoantigen initiated the disease, nor do we know the time point at which the antigenic challenge occurred. As clinicians we are faced with late-term manifestations of the immunologic events that lead to clinical disease. Finally, in limited forms of cutaneous autoimmune disease, it is important to recognize distinct subsets with a favorable prognosis, for which less aggressive therapeutic modalities may be used.

Autoimmune Diseases↗
PubMed2000

[Immunology in the medical practice. XXXIII. Hereditary immune deficiencies: from genotype to phenotype].

The advances of molecular biological techniques of the last decade have made possible identification of a rapidly increasing number of congenital (or primary) immune deficiencies at the genetic level. As soon as an immune deficiency is becoming a likely conclusion from a series of diagnostic laboratory tests, these recent developments in molecular techniques allow us in principle to make a conclusive diagnosis on the basis of a well-defined genetic defect. The hereditary immune deficiencies can be divided in 4 groups according to the functional immune aberration: antigen recognition, communication between immune cells, adhesion and directional motility, and killing as an effector mechanism.

Autoimmune Diseases↗